Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 3,800
- Avg volume
- —
- Day's range
- $0.28 – $0.28
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headq...
Show more
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 32 1 039 41 00
- Website
- https://celyad.com
- Address
- Axis Business Park, Rue Emile Francqui 6, Mont-Saint-Guibert, Belgium
Latest news
No headlines yet.
